Please login to the form below

Not currently logged in
Email:
Password:

Blueprint Medicines

This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.

Roche pays $775m upfront to access Blueprint’s RET programme

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn. Roche has expanded its existing collaboration with Blueprint Medicines, signing a new deal which will see it gain rights to the ... development of pralsetinib across multiple treatment settings where

Latest news

More from news
Approximately 5 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.

  • Spotlight on Patient Engagement Spotlight on Patient Engagement

    Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.

  • Open Conversations: Pathway to Launch Excellence Open Conversations: Pathway to Launch Excellence

    Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.

  • Deal Watch March 2016 Deal Watch March 2016

    Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....